Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-09-21 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains an investor relations release announcing positive Phase III clinical trial results for a drug (ACZ885) and provides detailed information about the study, drug, and forward-looking statements. The document is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing used to disclose material information to investors outside of the annual or quarterly report cycle. The document length is about 14,319 characters, which is consistent with a detailed regulatory announcement but not a full financial report. There is no indication that this is a presentation, call transcript, or other specific category. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-09-21 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC referencing the Form 20-F for the fiscal year ended December 31, 2010, which was filed earlier. The letter discusses an extension of time to respond to an SEC comment letter. The document is short (1104 characters) and is a correspondence related to a regulatory filing rather than the filing itself. It does not contain financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers correspondence and compliance communications with regulators.
2011-09-19 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes an investor relations release updating on the integration of Alcon, strategic priorities, growth potential, management changes, and forward-looking statements. It is not a full annual or quarterly report but rather a periodic update on company strategy, business integration, and management changes. The document is lengthy (15,000 characters) and contains substantive information beyond a simple announcement or certification. Form 6-K filings typically serve as interim reports or updates for foreign private issuers. Given the detailed financial and strategic information presented, this aligns best with an Interim / Quarterly Report (IR) classification rather than a simple announcement or regulatory filing. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2011-09-13 English
Regulatory Filings 2011
Regulatory Filings
2011-09-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an investor relations press release announcing the European Commission approval of a medication (Votubia) for a specific medical condition. The content is primarily a regulatory announcement about a product approval and related clinical information, not a financial report or earnings release. The document is not an annual or interim report, nor does it contain financial statements or detailed financial analysis. It is also not a call transcript, management change, or voting result announcement. Given the nature of the filing (Form 6-K) and the content being a regulatory announcement and press release, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely a brief notice of report publication, so RPA is not suitable. Therefore, the classification is RNS with high confidence.
2011-09-09 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC responding to comments on their Form 20-F filing for the fiscal year ended December 31, 2010. It discusses accounting treatment and valuation of a financial instrument related to the acquisition of Alcon shares, referencing IAS 39 and IFRS accounting standards. The letter is a regulatory correspondence addressing SEC staff comments and clarifying accounting positions rather than presenting a full financial report or audit. It does not contain financial statements or comprehensive financial data but is a response to regulatory inquiries about a previously filed annual report (Form 20-F). Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance and explanatory document related to a regulatory filing, not the filing itself or a standalone audit report.
2011-09-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.